首页> 外文期刊>Bioconjugate Chemistry >Characterization of Antibody Products Obtained through Enzymatic and Nonenzymatic Glycosylation Reactions with a Glycan Oxazoline and Preparation of a Homogeneous Antibody-Drug Conjugate via Fc N-Glycan
【24h】

Characterization of Antibody Products Obtained through Enzymatic and Nonenzymatic Glycosylation Reactions with a Glycan Oxazoline and Preparation of a Homogeneous Antibody-Drug Conjugate via Fc N-Glycan

机译:通过酶促和非酶糖基化反应获得的抗体产物的表征通过甘油恶唑啉,并通过Fc N-聚糖制备均相抗体 - 药物缀合物的制备

获取原文
获取原文并翻译 | 示例
       

摘要

Glycan engineering of antibodies has received considerable attention. Although various endo-beta-N-acetylglucosaminidase mutants have been developed for glycan remodeling, a side reaction has been reported between glycan oxazoline and amino groups. In this study, we performed a detailed characterization for antibody products obtained through enzymatic and nonenzymatic reactions with the aim of maximizing the efficiency of the glycosylation reaction with fewer side products. The reactions were monitored by an ultraperformance liquid chromatography system using an amide-based wide-pore column. The products were characterized by liquid chromatography coupled with tandem mass spectrometry. The side reactions were suppressed by adding glycan oxazoline in a stepwise manner under slightly acidic conditions. Through a combination of an azide-carrying glycan transfer reaction under optimized conditions and a bioorthogonal reaction, a potent cytotoxic agent monomethyl auristatin E was site-specifically conjugated at N-glycosylated Asn297 with a drug-to-antibody ratio of 4. The prepared antibody-drug conjugate exhibited cytotoxicity against HER2-expressing cells.
机译:糖粉的抗体工程受到相当大的关注。虽然已经开发了各种内β-N-乙酰葡糖胺酶突变体用于聚糖重塑,但在甘油恶唑啉和氨基之间已经报道了副反应。在该研究中,我们对通过酶促和非酶反应获得的抗体产物进行了详细表征,其目的是最大化糖基化反应与较少副产物的糖基化反应的效率。通过使用基于酰胺基宽孔柱的超细型液相色谱系统监测反应。该产品的特征在于液相色谱,偶联串联质谱法。通过在略微酸性条件下以逐步的方式加入聚糖恶唑啉来抑制副反应。通过在优化条件和生物正交反应下进行含叠氮化的聚糖转移反应的组合,效率的细胞毒剂单甲基AuristatIN E在N-糖基化的ASN297中在N-糖基化的ASN297中与4的药物 - 抗体比为4.制备的抗体-Drug缀合物表现出对Els2表达细胞的细胞毒性。

著录项

  • 来源
    《Bioconjugate Chemistry》 |2019年第5期|共13页
  • 作者单位

    RIKEN Synthet Cellular Chem Lab Wako Saitama 3510198 Japan;

    RIKEN Synthet Cellular Chem Lab Wako Saitama 3510198 Japan;

    RIKEN Struct Glycobiol Team Wako Saitama 3510198 Japan;

    Natl Canc Ctr Exploratory Oncol Res &

    Clin Trial Ctr Kashiwa Chiba 2778577 Japan;

    Nihon Waters KK Shinagawa Ku Tokyo 1400001 Japan;

    Nihon Waters KK Shinagawa Ku Tokyo 1400001 Japan;

    Fushimi Pharmaceut Co Ltd Marugame Kagawa 7638605 Japan;

    Fushimi Pharmaceut Co Ltd Marugame Kagawa 7638605 Japan;

    Fushimi Pharmaceut Co Ltd Marugame Kagawa 7638605 Japan;

    RIKEN Synthet Cellular Chem Lab Wako Saitama 3510198 Japan;

    Natl Canc Ctr Exploratory Oncol Res &

    Clin Trial Ctr Kashiwa Chiba 2778577 Japan;

    Natl Canc Ctr Exploratory Oncol Res &

    Clin Trial Ctr Kashiwa Chiba 2778577 Japan;

    RIKEN Synthet Cellular Chem Lab Wako Saitama 3510198 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;
  • 关键词

  • 入库时间 2022-08-19 23:05:25

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号